Financial Review: NewLink Genetics (NLNK) and Its Competitors
NewLink Genetics (NASDAQ: NLNK) is one of 190 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare NewLink Genetics to similar businesses based on the strength of its dividends, profitability, analyst recommendations, earnings, institutional ownership, valuation and risk.
This is a breakdown of recent recommendations for NewLink Genetics and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|NewLink Genetics Competitors||540||2467||6687||126||2.65|
This table compares NewLink Genetics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|NewLink Genetics Competitors||-3,262.51%||-525.94%||-39.29%|
Insider & Institutional Ownership
52.7% of NewLink Genetics shares are held by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.7% of NewLink Genetics shares are held by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares NewLink Genetics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|NewLink Genetics||$35.77 million||-$85.15 million||-3.49|
|NewLink Genetics Competitors||$217.29 million||-$39.39 million||-64.96|
NewLink Genetics’ competitors have higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
NewLink Genetics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, NewLink Genetics’ competitors have a beta of 1.57, indicating that their average stock price is 57% more volatile than the S&P 500.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
Receive News & Ratings for NewLink Genetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.